Safety of factor VIII inhibitor bypass activity (FEIBA^®): 10‐year compilation of thrombotic adverse events

Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel

2000 • 649 citations

Fortnightly review: Adverse drug reactions

1998 • 421 citations

The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study

1997 • 356 citations

The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIII

1981 • 303 citations

Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

1997 • 287 citations

Under-reporting of adverse drug reactions

1998 • 232 citations

The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors

1983 • 182 citations

Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

1990 • 131 citations

Prescription-event monitoring and reporting of adverse drug reactions

2001 • 128 citations

Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor

1999 • 113 citations

Pharmacovigilance in the pharmaceutical industry

1998 • 92 citations

Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients With Inherited and Acquired Bleeding Disorders

1993 • 90 citations

Inhibitors in hemophilia patients: Current status and management

1994 • 84 citations

Safety, efficacy and lessons from continuous infusion with rFVIIa

1998 • 77 citations

Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia a patients with inhibitors

1994 • 55 citations

Complications associated with the treatment of haemophiliacs with inhibitors

1999 • 47 citations

Adverse Events after Protamine Administration in Patients Undergoing Cardiopulmonary Bypass: Risks and Predictors of Under-Reporting

1998 • 44 citations

Treatment of Factor VIII Inhibitors: Products and Strategies

1993 • 40 citations

Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII

2000 • 38 citations

Management of haemophilia in patients with high‐titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX® T

1999 • 35 citations

Recombinant Factor VIIa Is a Pan-hemostatic Agent?

2000 • 35 citations

Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor

1992 • 29 citations

Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor.

1993 • 24 citations

Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A

1997 • 17 citations

Manifestations of Factor VIII Inhibitor in the Head and Neck

1999 • 12 citations

Epidemiology of Inhibitor Development in Haemophilia A Patients Treated with Virus– Inactivated Plasma–Derived Clotting Factor Concentrates

1999 • 12 citations

Acute myocardial infarction complicating therapy with F VIII followed by APCC and rFVIIa in a 26-year-old man with haemophilia A and F VIII inhibitor.

1998 • 9 citations

Management of anterior compartment syndrome in two high responder factor VIII inhibitor patients with activated prothrombin complex concentrate

1986 • 6 citations

Verlauf bei 13 Patienten mit erworbener Hemmkörperhämophilie

2000 • 1 citations